Get Nirmatrelvir-ritonavir Online

Nirmatrelvir-ritonavir is authorized for adults 18 and older who have tested positive for COVID-19, have mild to moderate symptoms, and are at high risk of progressing to severe illness. Risk factors include being 65 or older, obesity, diabetes, heart disease, chronic kidney disease, and being immunocompromised. Treatment must begin within 5 days of symptom onset.

Nirmatrelvir blocks the SARS-CoV-2 main protease, an enzyme the virus needs to replicate inside your cells. Ritonavir is added not as a direct antiviral but as a booster that slows the breakdown of nirmatrelvir by inhibiting the liver enzyme CYP3A4, keeping drug levels high enough to suppress the virus.

The standard adult dose is nirmatrelvir 300 mg (two 150 mg tablets) plus ritonavir 100 mg (one tablet) taken together twice daily for 5 days. Patients with moderate kidney impairment require a reduced dose. It should not be used in patients with severe kidney or severe liver disease.

The most commonly reported side effects include a metallic or altered taste (dysgeusia), diarrhea, high blood pressure, and muscle aches. Most side effects are mild and resolve after the 5-day course is completed.

Yes, ritonavir is a potent CYP3A inhibitor and can significantly raise or lower the blood levels of many common medications, including certain cholesterol medications (statins), blood thinners, heart rhythm drugs, and immunosuppressants. Your physician will review your full medication list before prescribing. Some medications may need to be temporarily paused during treatment.

Some patients experience a return of COVID-19 symptoms or a new positive test a few days after completing the 5-day course. This is called Paxlovid rebound. It appears to occur in a minority of patients and is generally mild. Current guidance does not recommend a routine second course of treatment for rebound, but you should contact your provider if symptoms worsen significantly.

Yes. Vaccination status does not determine eligibility. The key criteria are a confirmed positive COVID-19 test, mild to moderate symptoms that began within the last 5 days, and the presence of risk factors for severe disease. Vaccinated individuals who meet these criteria may still be prescribed nirmatrelvir-ritonavir.

Doctronic uses an AI-powered evaluation to collect your symptoms, medical history, and current medications. A licensed physician then reviews your information, determines whether nirmatrelvir-ritonavir is appropriate and safe for you, and issues a treatment plan. The entire process is HIPAA-compliant and available to adults 18 and older in any U.S. state.